Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

@article{Dillman1996ImprovedSI,
  title={Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.},
  author={R. Dillman and J. Herndon and S. L. Seagren and W. Eaton and M. Green},
  journal={Journal of the National Cancer Institute},
  year={1996},
  volume={88 17},
  pages={
          1210-5
        }
}
  • R. Dillman, J. Herndon, +2 authors M. Green
  • Published 1996
  • Medicine
  • Journal of the National Cancer Institute
  • BACKGROUND For many years, high dose radiation therapy was the standard treatment for patients with locally or regionally advanced non-small-cell lung cancer (NSCLC), despite a 5-year survival rate of only 3%-10% following such therapy. From May 1984 through May 1987, the Cancer and Leukemia Group B (CALGB) conducted a randomized trial that showed that induction chemotherapy before radiation therapy improved survival during the first 3 years of follow-up. PURPOSE This report provides data for… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 35 REFERENCES